Thursday, 30 July 2026

Indian corporate news, decoded into deal flow

NSE LIVE
NIFTY 50 INDIA VIX
as of
MARKETS
DEAL FLOW
Manba Finance Limited Releases Q1 FY27… ▲ Capex & Future Plans Filatex India Establishes Wholly Owned Step-Down… ▲ MERGERS & ACQUISITIONS PSP Projects Reports Strong Q1 FY27… ▲ Results Details CCL Products Reports Strong Q1 FY27… ▲ Results Details Mold-Tek Packaging Reports Record Q1 FY27… ▲ Results Details Deepak Fertilisers & Petrochemicals Corp Ltd… ▲ Results Details AVATAR Industries Incorporates Wholly Owned Subsidiary… ▲ Capex & Future Plans
Home / Company Results / Hester Biosciences Reports Strong Q1 FY27 Results; Standalone PAT Jumps 88%, Consolidated Profit Boosted by Exceptional Gain
RS · Company Results

Hester Biosciences Reports Strong Q1 FY27 Results; Standalone PAT Jumps 88%, Consolidated Profit Boosted by Exceptional Gain

Hester Biosciences Limited has announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), reporting strong growth in its standalone business and a sharp rise in consolidated profit, supported by improved operating performance and a one-time exceptional gain at its African subsidiary.

The company’s standalone business delivered healthy revenue growth and significant margin expansion, while consolidated net profit benefited from a debt restructuring at Hester Africa.

Standalone Financial Highlights (Q1 FY27)

  • Revenue from Operations: ₹726.60 million, up 14% YoY from ₹634.90 million
  • Operating EBITDA: ₹260.34 million, up 95% YoY
  • Profit After Tax (PAT): ₹147.11 million, up 88% YoY
  • Earnings Per Share (EPS): ₹17.29
  • Gross Profit Margin: Improved to 78% from 69% in Q1 FY26

Poultry Healthcare Drives Growth

The Poultry Healthcare Division remained the company’s key growth engine during the quarter.

Sales from the segment increased 48% year-on-year to ₹617.69 million, driven by:

  • Higher institutional sales
  • Stronger market penetration
  • Increased demand for feed supplements
  • Healthy growth in disinfectant products

Animal Healthcare Business Sees Temporary Decline

Revenue from the Animal Healthcare Division declined 50% YoY to ₹108.44 million.

The company attributed the decline to delays in government-sponsored livestock immunization tenders, which affected sales during the quarter.

Consolidated Profit Surges on Exceptional Gain

On a consolidated basis:

  • Revenue from Operations: ₹772.44 million, down 8% YoY
  • Profit After Tax (PAT): ₹967.32 million, up 459% YoY

While consolidated revenue declined due to lower contributions from the company’s operations in Nepal and Africa, net profit increased sharply because of an exceptional gain of ₹853.49 million recorded at Hester Africa.

Debt Restructuring at Hester Africa

The exceptional gain arose following the restructuring of a loan provided by the Gates Foundation to Hester Africa.

Under the revised agreement:

  • The outstanding loan principal was reduced from USD 12 million to USD 5 million.
  • Accrued interest on the loan was waived.
  • The remaining loan was converted into an interest-free facility.

The accounting impact of these changes resulted in the one-time exceptional gain recorded during the quarter.